An adrenergic agonist is ordered for a patient in shock. The nurse will note that this drug has had its primary intended effect if which expected outcome occurs?
Decreased urine output
Increased cardiac output
Volume restoration
Reduced anxiety
The Correct Answer is B
A. Decreased urine output is not the primary intended effect of an adrenergic agonist in the
treatment of shock. While adrenergic agonists may increase blood pressure, leading to a decrease in urine output due to vasoconstriction, the primary goal of administering these drugs in shock is to improve tissue perfusion and cardiac output.
B. Increased cardiac output is the primary intended effect of adrenergic agonists in the treatment of shock. These medications stimulate adrenergic receptors, leading to increased heart rate, contractility, and stroke volume, ultimately improving cardiac output and tissue perfusion.
C. Volume restoration may be a secondary effect of administering fluids along with adrenergic agonists in the treatment of shock, but it is not the primary intended effect of the medication
itself.
D. Reduced anxiety is not a primary goal of administering adrenergic agonists in the treatment of shock. While these medications may have anxiolytic effects in certain situations, the primary goal is to improve cardiovascular function and tissue perfusion.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is A
Explanation
A. Decreased weight: Orlistat is a medication used for weight management by inhibiting the absorption of dietary fats. Its intended therapeutic effect is to promote weight loss by reducing the amount of fat absorbed from the diet.
B. Increased appetite: Orlistat does not increase appetite; rather, it may help control appetite by promoting satiety through its mechanism of action.
C. Decreased hyperactivity: Orlistat is not indicated for the treatment of hyperactivity.
D. Increased wakefulness: Orlistat does not affect wakefulness; it primarily acts in the gastrointestinal tract to inhibit fat absorption.
Correct Answer is A
Explanation
A. Carbidopa prevents the breakdown of levodopa in the periphery, specifically in the gastrointestinal tract and peripheral tissues, allowing more levodopa to reach the brain and be converted to dopamine. This enhances the effectiveness of levodopa therapy in managing the symptoms of Parkinson's disease.
B. Carbidopa is not the biologic precursor of dopamine. It is a peripheral decarboxylase inhibitor that does not cross the blood-brain barrier.
C. Carbidopa does not directly allow for larger doses of levodopa to be given. However, by
inhibiting the peripheral breakdown of levodopa, it enhances the availability of levodopa to the central nervous system, potentially improving therapeutic efficacy.
D. While levodopa-carbidopa combination therapy may have fewer drug-food interactions compared to levodopa alone, the primary reason for combining these medications is to enhance the effectiveness of levodopa by preventing its peripheral breakdown.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.